



***Annual General Meeting***  
**July 29, 2010**



## 2009 Summary Delivering on Our Innovation Plan

### ▣ Quill™ SRS

- Record sales
- 1,000+ hospital accounts
- Opportunity to grow into a significant brand with added investments in commercial and R & D



### ▣ Option IVC Filter

- Launch exceeding initial expectations
- Tracking well toward objective of #2 or #3 share by year end 2010
- Continued positive retrieval data at longer post-implant durations



### ▣ Base Business

- Strong leadership and management
- Stable to improving business and customer climate
- Optimistic about return to growth in 2010
- Opportunities exist to improve cash flow generated from existing sales







## 2010 Focal Points Delivering on Our Innovation Plan

### ❑ **Quill™ SRS**

- Record sales
- 1,300+ hospital accounts
- Additional procedure-specific innovations set to launch in 2010
- 2010 Medical Device Excellence Award



### ❑ **Athersys**

- MultiStem Phase I clinical study results: well tolerated at all dose levels and clinical data also suggests improvement in heart function in treated patients



### ❑ **Haemacure Acquisition**

- Assets acquired in April and currently integrating within corporate structure
- Product candidates aligned with drug-loaded hydrogel pipeline



### ❑ **Cook Medical: Zilver® PTX® Drug-Eluting Peripheral Stent**

- Submitted PMA for FDA review

